154 related articles for article (PubMed ID: 25350844)
1. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.
Hong YS; Kim J; Pectasides E; Fox C; Hong SW; Ma Q; Wong GS; Peng S; Stachler MD; Thorner AR; Van Hummelen P; Bass AJ
PLoS One; 2014; 9(10):e109440. PubMed ID: 25350844
[TBL] [Abstract][Full Text] [Related]
2. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
De Silva N; Schulz L; Paterson A; Qain W; Secrier M; Godfrey E; Cheow H; O'Donovan M; Lao-Sirieix P; Jobanputra M; Hochhauser D; Fitzgerald R; Ford H
Br J Cancer; 2015 Nov; 113(9):1305-12. PubMed ID: 26484410
[TBL] [Abstract][Full Text] [Related]
3. Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells.
Janser FA; Adams O; Bütler V; Schläfli AM; Dislich B; Seiler CA; Kröll D; Langer R; Tschan MP
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30297650
[TBL] [Abstract][Full Text] [Related]
4. ERBB2 amplifications in esophageal adenocarcinoma.
Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
[TBL] [Abstract][Full Text] [Related]
5. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.
Kim J; Fox C; Peng S; Pusung M; Pectasides E; Matthee E; Hong YS; Do IG; Jang J; Thorner AR; Van Hummelen P; Rustgi AK; Wong KK; Zhou Z; Tang P; Kim KM; Lee J; Bass AJ
J Clin Invest; 2014 Dec; 124(12):5145-58. PubMed ID: 25401468
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
7. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Press MF; Ellis CE; Gagnon RC; Grob TJ; Buyse M; Villalobos I; Liang Z; Wu S; Bang YJ; Qin SK; Chung HC; Xu J; Park JO; Jeziorski K; Afenjar K; Ma Y; Estrada MC; Robinson DM; Scherer SJ; Sauter G; Hecht JR; Slamon DJ
Mol Cancer Ther; 2017 Jan; 16(1):228-238. PubMed ID: 27811012
[TBL] [Abstract][Full Text] [Related]
8. Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Xia W; Liu Z; Zong R; Liu L; Zhao S; Bacus SS; Mao Y; He J; Wulfkuhle JD; Petricoin EF; Osada T; Yang XY; Hartman ZC; Clay TM; Blackwell KL; Lyerly HK; Spector NL
Mol Cancer Ther; 2011 Aug; 10(8):1367-74. PubMed ID: 21673090
[TBL] [Abstract][Full Text] [Related]
9. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Trowe T; Boukouvala S; Calkins K; Cutler RE; Fong R; Funke R; Gendreau SB; Kim YD; Miller N; Woolfrey JR; Vysotskaia V; Yang JP; Gerritsen ME; Matthews DJ; Lamb P; Heuer TS
Clin Cancer Res; 2008 Apr; 14(8):2465-75. PubMed ID: 18413839
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
11. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
Jegg AM; Ward TM; Iorns E; Hoe N; Zhou J; Liu X; Singh S; Landgraf R; Pegram MD
Breast Cancer Res Treat; 2012 Dec; 136(3):683-92. PubMed ID: 23089982
[TBL] [Abstract][Full Text] [Related]
12. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
13. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
Kancha RK; von Bubnoff N; Bartosch N; Peschel C; Engh RA; Duyster J
PLoS One; 2011; 6(10):e26760. PubMed ID: 22046346
[TBL] [Abstract][Full Text] [Related]
14. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
Xia W; Bacus S; Hegde P; Husain I; Strum J; Liu L; Paulazzo G; Lyass L; Trusk P; Hill J; Harris J; Spector NL
Proc Natl Acad Sci U S A; 2006 May; 103(20):7795-800. PubMed ID: 16682622
[TBL] [Abstract][Full Text] [Related]
15. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.
Wetterskog D; Shiu KK; Chong I; Meijer T; Mackay A; Lambros M; Cunningham D; Reis-Filho JS; Lord CJ; Ashworth A
Oncogene; 2014 Feb; 33(8):966-76. PubMed ID: 23474757
[TBL] [Abstract][Full Text] [Related]
17. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
19. Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
Li G; Wang X; Hibshoosh H; Jin C; Halmos B
PLoS One; 2014; 9(9):e106349. PubMed ID: 25238247
[TBL] [Abstract][Full Text] [Related]
20. ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas.
Arrington AK; Dahlberg PS; Davydova J; Vickers SM; Yamamoto M
Surgery; 2009 Aug; 146(2):213-9. PubMed ID: 19628076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
